NCT03513406View on ClinicalTrials.gov

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

March 7, 2023

Study Completion Date

March 7, 2023

Conditions

Burns

Interventions

DRUG

Sugammadex

Sugammadex is indicated for the reversal of neuromuscular blockade.

DRUG

Neostigmine

Neostigmine is indicated for the reversal of neuromuscular blockade.

DRUG

Glycopyrrolate

Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors

lead

University of Kansas Medical Center

OTHER

NCT03513406 - Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery | Biotech Hunter | Biotech Hunter